Ascorbic Acid to Prevent Postreperfusion Syndrome in Liver Transplantation
Status:
Recruiting
Trial end date:
2023-07-30
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to test the efficacy of intravenous ascorbic acid in
preventing the postreperfusion syndrome in liver transplantation. The main questions it aims
to answer are:
- Can intravenous ascorbic acid prevent postreperfusion syndrome in liver transplantation
?
- Can ascorbic acid decrease the incidence of liver graft dysfunction after liver
transplantation?
- Can ascorbic acid decreased the incidence of postoperative complications after liver
transplantation ?
Participants will receive 1.5 g of intravenous ascorbic acid diluted in 100 ml of saline or
100 ml of saline alone, during the anhepatic phase of liver transplantation before
reperfusion of the new graft.
Researchers will compared the incidence of postreperfusion syndrome in both groups.